Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Standard BioTools Inc shares valued at $1,344 were sold by Kim Hanjoon Alex on May 23 ’25. At $0.94 per share, Kim Hanjoon Alex sold 1,428 shares. The insider’s holdings dropped to 930,286 shares worth approximately $1.19 million following the completion of this transaction.
Also, Mackay Sean sold 13,217 shares, netting a total of over 12,437 in proceeds. Following the sale of shares at $0.94 each, the insider now holds 843,076 shares.
Before that, Egholm Michael had sold 5,473 shares from its account. In a trade valued at $5,150, the President & CEO traded Standard BioTools Inc shares for $0.94 each. Upon closing the transaction, the insider’s holdings decreased to 5,473 shares, worth approximately $3.51 million.
As published in a research note from KeyBanc Capital Markets on February 27, 2025, Standard BioTools Inc [LAB] has been rated down from an Overweight to a Sector weight. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid April. As of April 04, 2024, Jefferies has initiated its “Buy” rating for LAB. Earlier on July 12, 2023, KeyBanc Capital Markets initiated its rating. Their recommendation was “an Overweight” for LAB stock.
Analyzing LAB Stock Performance
On last trading session, Standard BioTools Inc [NASDAQ: LAB] plunged -1.54% to $1.28. The stock’s lowest price that day was $1.27, but it reached a high of $1.31 in the same session. During the last five days, there has been a drop of approximately -7.25%. Over the course of the year, Standard BioTools Inc shares have dropped approximately -22.42%.
Is Standard BioTools Inc subject to short interest?
Stocks of Standard BioTools Inc saw a sharp steep in short interest on 2025-07-15 dropping by -3.82 million shares to 12.34 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 16.16 million shares. A decline of -31.0% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.27 of the overall float, the days-to-cover ratio (short ratio) decline to 4.27.
Which companies own the most shares of Standard BioTools Inc (LAB)?
In terms of Standard BioTools Inc share price expectations, FactSet research, analysts set an average price target of 3.25 in the next 12 months, up nearly 150.0% from the previous closing price of $1.3. Analysts anticipate Standard BioTools Inc stock to reach 3.25 by 2025, with the lowest price target being 3.25. In spite of this, 3 analysts ranked Standard BioTools Inc stock as Buy at the end of 2025.
